Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $19.00 Average Price Target from Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $19.00.

FULC has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Thursday, January 22nd. Bank of America lifted their target price on Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a research report on Tuesday, December 9th. Leerink Partners reiterated an “outperform” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. Finally, Royal Bank Of Canada boosted their price target on Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a research report on Monday, December 8th.

Fulcrum Therapeutics Stock Down 2.6%

FULC opened at $7.83 on Friday. Fulcrum Therapeutics has a 52 week low of $2.32 and a 52 week high of $15.74. The business has a fifty day simple moving average of $8.84 and a 200-day simple moving average of $9.64. The firm has a market cap of $521.48 million, a P/E ratio of -6.64 and a beta of 3.27.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.31) EPS for the quarter, hitting the consensus estimate of ($0.31). Sell-side analysts expect that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Hedge Funds Weigh In On Fulcrum Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in Fulcrum Therapeutics in the 4th quarter valued at about $30,000. Quarry LP acquired a new position in Fulcrum Therapeutics in the 3rd quarter valued at about $35,000. Meeder Asset Management Inc. acquired a new position in Fulcrum Therapeutics in the 4th quarter valued at about $39,000. Russell Investments Group Ltd. increased its position in Fulcrum Therapeutics by 4,209.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after acquiring an additional 9,092 shares during the period. Finally, Farther Finance Advisors LLC increased its position in Fulcrum Therapeutics by 108.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after acquiring an additional 3,697 shares during the period. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.